Xell specializes in advanced cell culture technology, providing high-performance culture media and feeds tailored for various human cell lines, including HEK and CHO cells. Their offerings include ready-to-use media for the production of viral vectors, such as AAVs and lentiviruses, which are essential for gene therapy applications. Xell also emphasizes the importance of analytical services, utilizing sophisticated methods for analyzing media components and developing customized solutions to meet specific client needs. This focus on high-quality, chemically-defined media supports long-term, high-performance cell culture, particularly for protein production.

In addition to their media products, Xell offers a range of related services, including media and process development, suspension adaptation, and cell studies. Their commitment to innovation is evident in their contract production capabilities, which allow for the animal component-free manufacturing of cell culture media and buffers. By integrating these services with their high-performance products, Xell positions itself as a versatile partner in the biotech and pharmaceutical industries, addressing the diverse challenges faced in cell culture technology.

Germany

Xell is a Germany-based biotech company that develops, produces and markets media and feed supplements for gene therapeutics and vaccines.

Xell

Company Details